Otsuka Pharmaceutical Company, Limited

Tomoichi Shinohara

Nobuaki Ito

Hirofumi Sasaki

Kuninori Tai

Muneaki Kurimura

Takayuki Matsuzaki

Takahiro Tomoyasu

Michiaki Tominaga

Shin Miyamura

Yasuhiro Menjo

Yohji Sakurai

Shinichi Taira

Noriaki Takemura

Yoshihisa Tanada

Yasuyo Sakata

Akihito Watanabe

Takumi Masumoto

Kohei Akazawa

Haruhiko Sugino

Naoki Amada

Satoshi Ohashi

Chisako Morita

Junko Yamashita

Satoko Nakajima

Hidenori Ogawa

Yoichi Yabuuchi

Kazumi Kondo

Keizo Kan

Hiroshi Yamashita

Takahito Yamauchi

Masaki Suzuki

Takeshi Kuroda

Kunio Oshima

Takumi Sumida

Toyoki Mori

Tae Fukushima

Hironobu Ishiyama

Kazuhide Ohta

Hitoshi Nagao

Kenta Arai

Chiharu Kitajima

Masaaki Takano

Shin Iwata

Kaoru Abe

Minoru Uchida

Kenji Nakaya

Isao Takemura

Fujio Tabusa

Kazuyoshi Nagami

Seiji Morita

Takuya Chiba

Harukiho Sugino

The present invention provides a novel heterocyclic compound represented by Formula [I] and a salt thereof: wherein the symbols are as defined in the specification, which is useful for treating, preventing and/or diagnosing seizure and the like in disease involving epileptic seizure or convulsive seizure (including multiple drug resistant seizure, refractory seizure, acute symptomatic seizure, febrile seizure and status epilepticus), as well as a medical use therefor.

Heterocyclic compounds for the treatment of epilepsy

A heterocyclic compound represented by the general formula (1) or a salt thereof: 

Methods of treating anxiety by administering a substituted quinolone

The present invention provides a novel pyrimidine compound represented by Formula [I] and a salt thereof: [in the formula, the symbols are as defined in the specification], which is useful for treating, preventing and/or diagnosing seizure and the like in disease involving epileptic seizure or convulsive seizure (including multiple drug resistant seizure, refractory seizure, acute symptomatic seizure, febrile seizure and status epilepticus), as well as a medical use therefor.

Pyrimidine compound

Method of treating disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine

Method for treating depression and/or depression status with substituted quinoxaline compounds

The present invention provides a pyrrolidine compound of General Formula (1) or a salt thereof, wherein Rand Rare each independently a phenyl group or a pyridyl group, the phenyl group or the pyridyl group may have one or more substituents selected from halogen atoms and lower alkyl groups optionally substituted with one or more halogen atoms, etc. The pyrrolidine compound or a salt thereof of the present invention is usable to produce a pharmaceutical preparation having a wider therapeutic spectrum and being capable of exhibiting sufficient therapeutic effects after short-term administration.

N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors

A heterocyclic compound represented by the general formula (1) or a salt thereof: wherein m, l, and n respectively represent an integer of 1 or 2; X represents &#x2014;O&#x2014; or &#x2014;CH&#x2014;;Rrepresents hydrogen, a lower alkyl group, a hydroxy-lower alkyl group, a protecting group, or a tri-lower alkylsilyloxy-lower alkyl group;Rand R, which are the same or different, each independently represent hydrogen or a lower alkyl group; or Rand Rare bonded to form a cyclo-C3-C8 alkyl group; andRrepresents an aromatic group or a heterocyclic group, wherein the aromatic or heterocyclic group may have one or more arbitrary substituent(s).

Substituted quinoxalines compounds

N, N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors

The present invention provides a carbostyril compound represented by General Formula (1) or a salt thereof, wherein A is a direct bond, a lower alkylene group, or a lower alkylidene group; X is an oxygen atom or a sulfur atom; Rand Reach represent a hydrogen atom; the bond between the 3 and 4 positions of the carbostyril skeleton is a single bond or a double bond; Ris a hydrogen atom, etc; Ris a hydrogen atom, etc; and Ris a hydrogen atom, etc. The carbostyril compound or salt thereof of the present invention induces the production of TFF, and thus is usable for the treatment and/or prevention of disorders such as alimentary tract diseases, oral diseases, upper respiratory tract diseases, respiratory tract diseases, eye diseases, cancers, and wounds.

Carbostyril compound

Benzoheterocyclic derivatives

Growing community of inventors

Tokushima, Japan

Tomoichi Shinohara